ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $365 | $410 | $259 | $0 |
| G&A Expenses | $1,739 | $1,634 | $1,886 | $1 |
| SG&A Expenses | $1,739 | $1,634 | $1,886 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $18,648 | -$2,042 | -$2,142 | $0 |
| Operating Expenses | $20,752 | $2 | $2 | $1 |
| Operating Income | -$20,752 | -$2,044 | -$2,145 | -$1 |
| % Margin | – | – | – | -4,933.7% |
| Other Income/Exp. Net | $1,798 | -$167 | -$112 | -$0 |
| Pre-Tax Income | -$18,954 | -$2,211 | -$2,257 | -$1 |
| Tax Expense | $852 | $0 | $0 | -$0 |
| Net Income | -$19,806 | -$2 | -$2 | -$1 |
| % Margin | – | – | – | -5,451.7% |
| EPS | -2.56 | -0.46 | -0.73 | -1.31 |
| % Growth | -456.5% | 37% | 44.3% | – |
| EPS Diluted | -2.56 | -0.46 | -0.73 | -1.31 |
| Weighted Avg Shares Out | 77 | 48 | 3 | 1 |
| Weighted Avg Shares Out Dil | 77 | 48 | 3 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $131 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$20,752 | -$2 | -$2 | -$1 |
| % Margin | – | – | – | -4,933.7% |